Zhang Song-Yi 4
Accession 0001209191-18-042455
Filed
Jul 11, 8:00 PM ET
Accepted
Jul 12, 4:16 PM ET
Size
21.7 KB
Accession
0001209191-18-042455
Insider Transaction Report
- Award
Common Stock
2016-06-29+107,181→ 107,181 total(indirect: By Avalon Polytom (HK) Limited)
- 5,554,914(indirect: By Mandra Medical Limited)
Common Stock
- 4,000
Common Stock
- 678,880(indirect: By Avalon Biomedical (Management) Limited)
Common Stock
- 181,818(indirect: By iBase Ltd.)
Common Stock
- 287,176(indirect: By Mandra Health Limited)
Common Stock
- 48,000
Stock Option (Right to Buy)
Exercise: $9.00From: 2017-10-17Exp: 2025-10-17→ Common Stock (48,000 underlying) - 28,500
Stock Option (Right to Buy)
Exercise: $11.00Exp: 2027-06-14→ Common Stock (28,500 underlying) - 54,904(indirect: By Avalon Biomedical (Management) Limited)
Stock Option (Right to Buy)
Exercise: $9.00Exp: 2025-07-17→ Common Stock (54,904 underlying) - 80,000
Stock Option (Right to Buy)
Exercise: $7.50From: 2016-05-18Exp: 2025-05-18→ Common Stock (80,000 underlying)
- Award
Common Stock
2016-06-29+107,181→ 107,181 total(indirect: By Avalon Polytom (HK) Limited)
- 181,818(indirect: By iBase Ltd.)
Common Stock
- 287,176(indirect: By Mandra Health Limited)
Common Stock
- 48,000
Stock Option (Right to Buy)
Exercise: $9.00From: 2017-10-17Exp: 2025-10-17→ Common Stock (48,000 underlying) - 80,000
Stock Option (Right to Buy)
Exercise: $7.50From: 2016-05-18Exp: 2025-05-18→ Common Stock (80,000 underlying) - 678,880(indirect: By Avalon Biomedical (Management) Limited)
Common Stock
- 28,500
Stock Option (Right to Buy)
Exercise: $11.00Exp: 2027-06-14→ Common Stock (28,500 underlying) - 54,904(indirect: By Avalon Biomedical (Management) Limited)
Stock Option (Right to Buy)
Exercise: $9.00Exp: 2025-07-17→ Common Stock (54,904 underlying) - 5,554,914(indirect: By Mandra Medical Limited)
Common Stock
- 4,000
Common Stock
- Award
Common Stock
2016-06-29+107,181→ 107,181 total(indirect: By Avalon Polytom (HK) Limited)
- 4,000
Common Stock
- 678,880(indirect: By Avalon Biomedical (Management) Limited)
Common Stock
- 80,000
Stock Option (Right to Buy)
Exercise: $7.50From: 2016-05-18Exp: 2025-05-18→ Common Stock (80,000 underlying) - 48,000
Stock Option (Right to Buy)
Exercise: $9.00From: 2017-10-17Exp: 2025-10-17→ Common Stock (48,000 underlying) - 5,554,914(indirect: By Mandra Medical Limited)
Common Stock
- 181,818(indirect: By iBase Ltd.)
Common Stock
- 28,500
Stock Option (Right to Buy)
Exercise: $11.00Exp: 2027-06-14→ Common Stock (28,500 underlying) - 54,904(indirect: By Avalon Biomedical (Management) Limited)
Stock Option (Right to Buy)
Exercise: $9.00Exp: 2025-07-17→ Common Stock (54,904 underlying) - 287,176(indirect: By Mandra Health Limited)
Common Stock
- Award
Common Stock
2016-06-29+107,181→ 107,181 total(indirect: By Avalon Polytom (HK) Limited)
- 287,176(indirect: By Mandra Health Limited)
Common Stock
- 48,000
Stock Option (Right to Buy)
Exercise: $9.00From: 2017-10-17Exp: 2025-10-17→ Common Stock (48,000 underlying) - 80,000
Stock Option (Right to Buy)
Exercise: $7.50From: 2016-05-18Exp: 2025-05-18→ Common Stock (80,000 underlying) - 678,880(indirect: By Avalon Biomedical (Management) Limited)
Common Stock
- 54,904(indirect: By Avalon Biomedical (Management) Limited)
Stock Option (Right to Buy)
Exercise: $9.00Exp: 2025-07-17→ Common Stock (54,904 underlying) - 5,554,914(indirect: By Mandra Medical Limited)
Common Stock
- 4,000
Common Stock
- 181,818(indirect: By iBase Ltd.)
Common Stock
- 28,500
Stock Option (Right to Buy)
Exercise: $11.00Exp: 2027-06-14→ Common Stock (28,500 underlying)
Footnotes (7)
- [F1]Each of Mandra Health Limited and Mandra Medical Limited are wholly-owned subsidiaries of Beansprouts Limited. Song-Yi Zhang ("Mr. Zhang") is a member of the board of directors of each of Mandra Health Limited and Mandra Medical Limited and, together with his spouse, own all of the outstanding interests in Beansprouts Limited and shares voting and dispositive power over the shares held by it.
- [F2]Mr. Zhang disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Zhang is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F3]Mr. Zhang is the sole owner and director of iBase Ltd. and has sole voting and dispositive power over the shares held by iBase Ltd.
- [F4]Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect, wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mr. Zhang, together with his spouse, indirectly own all of the outstanding interests in Mandra Medical Limited, which owns 10.82% of the outstanding interests in Avalon Global, and Mr. Zhang serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
- [F5]These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
- [F6]This option vests in four equal annual installments beginning on June 14, 2018.
- [F7]This option vests in three equal annual installments beginning on July 17, 2016.
Documents
Issuer
Athenex, Inc.
CIK 0001300699
Related Parties
1- filerCIK 0001290865
Filing Metadata
- Form type
- 4
- Filed
- Jul 11, 8:00 PM ET
- Accepted
- Jul 12, 4:16 PM ET
- Size
- 21.7 KB